TL;DR
Cancer-associated fibroblasts (CAFs) create a niche that shields ovarian cancer stem cells (CSCs) from chemotherapy by secreting Wnt5a. This Wnt5a activates a noncanonical Wnt signaling pathway in CSCs, promoting their self-renewal and resistance. Targeting this Wnt5a-driven interaction could be a new strategy to combat ovarian cancer relapse and chemoresistance.
What Problem Does This Paper Address?
Ovarian cancer (OC) often relapses and becomes resistant to chemotherapy, leading to poor patient outcomes. While cancer stem cells (CSCs) are known contributors to this, the role of the tumor microenvironment (TME) in supporting CSCs and driving chemoresistance has been less understood. Specifically, how cancer-associated fibroblasts (CAFs), a major component of the OC TME, interact with and maintain CSCs in a way that promotes resistance is a key question. This paper aims to elucidate the specific signaling mechanisms by which CAFs create a "niche" that protects and propagates CSCs, contributing to OC relapse and chemoresistance.
Methods
The researchers employed a multi-pronged approach:
- In vitro cocultures: They used heterotypic cocultures of ovarian cancer cells (including cell lines like OVCAR3 and patient-derived ascites cells) and CAFs. This allowed them to study direct interactions and the effects of CAF-secreted factors.
- ALDEFLUOR assay: This assay was used to identify and quantify cancer stem cells (CSCs), which are characterized by high aldehyde dehydrogenase (ALDH) activity.
- Spheroid formation assay: This method assesses the stemness and self-renewal capacity of cancer cells, as CSCs are known to form non-adherent spheres.
- In vivo limiting dilution assay: This gold-standard assay in cancer stem cell research was used to determine the tumor-initiating potential of cells under different conditions.
- Single-cell RNA sequencing (scRNA-seq): They analyzed scRNA-seq data from OC patients to identify specific Wnt ligands expressed by CAFs and their potential targets in cancer cells.
- Molecular inhibition and knockdown: They used Wnt5a inhibitors (Box5), a PORCN inhibitor (IWP2), and siRNA to knock down specific genes (e.g., WNT5A, PORCN, ROR2, CREB1) to dissect the signaling pathways involved.
- Immunohistochemistry and Immunoblotting: These techniques were used to visualize protein expression and activation in cells and tumor tissues.
- Interface interaction assay: A novel setup was designed to study the localized effects of CAFs on OC cells by creating a defined interface between them.
- Xenograft models: Mouse models were used to test the efficacy of combination therapies in vivo.
Datasets
- TCGA ovarian cancer data: Used for initial analysis of fibroblast scores in relation to tumor stage.
- Australian Ovarian Cancer Study (AOCS) dataset (GSE9891): Used for profiling gene expression in chemo-resistant vs. chemo-sensitive ovarian cancer samples and analyzing WNT5A expression in relation to CSC markers.
- 11 HGSOC patient scRNA-seq data (GSE165897): Crucial for identifying Wnt expression patterns in CAFs and cancer cells and for inferring cell-cell communication pathways.
Key Insights and Ideas
- CAFs are not just passive bystanders: They actively create a niche that supports CSCs, making them more resistant to chemotherapy.
- Wnt5a is the key CAF signal: CAFs secrete Wnt5a, which is the primary mediator of their pro-CSC effects. This is a novel finding in the context of CAF-CSC interactions in OC.
- Noncanonical Wnt signaling is critical: Unlike canonical Wnt signaling, which is more prevalent between cancer cells, CAFs engage cancer cells through a noncanonical Wnt pathway.
- ROR2 is the essential CAF-CSC receptor: Wnt5a from CAFs signals through the ROR2 receptor on CSCs, activating downstream pathways.
- Localized effect: The protective and stemness-inducing effects of CAFs are primarily limited to cancer cells in their immediate vicinity, suggesting a paracrine or juxtacrine signaling mechanism.
- Therapeutic vulnerability: Inhibiting Wnt5a, either alone or in combination with chemotherapy, shows promise in reducing CSC populations and improving treatment outcomes.
Key Results
- CAFs significantly increased OC cell resistance to carboplatin in vitro and in vivo.
- Coculturing with CAFs increased the number of ALDH+ cells (CSCs) and spheroid formation in OC cells.
- In vivo limiting dilution assays showed that CAFs increased the tumor-initiating cell frequency of OC cells by 10-fold.
- scRNA-seq analysis revealed Wnt5a as the most highly expressed Wnt in CAFs, and its expression was higher in CAFs from OC patients compared to normal fibroblasts.
- Treatment with a Wnt5a inhibitor (Box5) reduced OCSC induction and sensitized tumors to carboplatin in vivo.
- Knocking down WNT5A in CAFs abrogated their ability to induce OCSCs.
- The noncanonical Wnt signaling pathway involving ROR2, PKC, and CREB1 was identified as the key mediator of Wnt5a-induced OCSC maintenance.
- Inhibition of ROR2 significantly reduced ALDH activity and spheroid formation in OC cells.
- Combination therapy with carboplatin and a Wnt5a inhibitor was more effective in reducing tumor growth and residual OCSCs in xenograft models than either treatment alone.
Limitations and Future Work
- Heterogeneity of CAFs: The authors acknowledge that CAFs are a heterogeneous population and suggest further studies are needed to characterize specific Wnt5a-expressing CAF subpopulations that serve as OCSC niches.
- Context-dependent Wnt5a effects: Wnt5a's effects can be context-dependent, and while this study focused on noncanonical pathways, further exploration of its broader roles might be beneficial.
- Clinical translation: While promising, the findings need to be validated in larger clinical trials. The authors suggest that targeting Wnt5a with therapies that combine it with standard chemotherapy could be a viable strategy to reduce disease recurrence. Future work could focus on developing more specific Wnt5a inhibitors and evaluating their efficacy and safety in clinical settings.
Summary updated